A recent study conducted by Mount Sinai School of Medicine has called into question the effectiveness of beta blockers, a common medication prescribed after heart attacks. The findings, published in The New England Journal of Medicine, stem from the REBOOT trial involving 8,505 patients in Spain and Italy. The study revealed that beta blockers did not significantly lower the risk of repeated heart attacks, deaths, or hospitalizations for patients whose heart function remained normal post-attack. Notably, the study indicated that women prescribed beta blockers faced a 2.7% increased risk of death compared to those who did not take the medication. Given that beta blockers have been a staple in heart attack treatment for nearly 40 years and represent about 16% of the anti-hypertensive market in India, these findings could prompt a reevaluation of treatment protocols. Experts suggest that discontinuing the use of ineffective drugs may streamline treatment and mitigate associated side effects.